Memphasys (MEM) Stock Price, News & Analysis

Company Overview

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a device separates sperm from raw semen by electrophoresis process for use in human IVF procedures. In addition, the company's product pipeline include ROSA, a rapid oxidative stress assay; Samson Device, rapid equine pregnancy prediction assay; SemPort, a system that allows transport of semen; and AI-Port. Further, it provides ambient temperature storage product for human sperm. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 246,322 shs
• Average Volume: N/A
• Market Capitalization: A$14.17 million
• P/E Ratio: N/A
• Dividend Yield: 6.20%
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:MEM
• CIK: N/A
• Web: www.memphasys.com
• Phone: 61 2 8415 7300
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$4.44 million
• Net Margins: -7,403.37%
• Pretax Margin: N/A
• Return on Equity: -66.03%
• Return on Assets: -17.88%

Debt

• Debt-to-Equity Ratio: 70.33
• Current Ratio: 0.31
• Quick Ratio: 0.39

Sales & Book Value

• Annual Sales: A$1.09 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 12.20
• Book Value: A$0.00 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,450,000,000
• Free Float: N/A
• Market Cap: A$14.17 million
• Optionable: Not Optionable
• Beta: 0.95